Status:

COMPLETED

Optimal VAsopressor titraTION Pilot Randomized Controlled Trial

Lead Sponsor:

Francois Lamontagne

Collaborating Sponsors:

Canadian Critical Care Trials Group

Canadian Institutes of Health Research (CIHR)

Conditions:

Hypotension

Shock

Eligibility:

All Genders

17+ years

Phase:

NA

Brief Summary

The purpose of this research study is to determine if it is better to give vasopressors to patients to maintain a higher blood pressure target versus a lower blood pressure target. This study is impor...

Detailed Description

Patients who are admitted to the intensive care unit (ICU) commonly suffer from shock, a condition that causes life-threatening low blood pressure. Low blood pressure makes it difficult for the body t...

Eligibility Criteria

Inclusion

  • Who are receiving vasopressors for distributive shock
  • Who are older than 16 years of age at the time of eligibility.
  • Who are under the direct care of the ICU team regardless of location.
  • Who have received a minimum of 30 mL/kg of intravenous fluids (2100 mL for a 70 kg patient) before enrolment OR the most responsible physician has good reasons to believe that more fluid resuscitation is no longer required and could be harmful.
  • Who the treating physician believes will need vasopressors for at least 6 hours once enrolled.

Exclusion

  • Have received vasopressors for more than 24 consecutive hours; if vasopressors are discontinued for \>= 2 hours then restarting vasopressors will constitute a distinct vasopressor episode and the clock will be reset.
  • Are judged by the treating physician to be in obvious cardiogenic shock after an acute myocardial infarction (based on new ST segment elevations on ECG or obvious echocardiographic findings).
  • Have obvious haemorrhagic shock as a consequence of a clearly identified source of blood loss.
  • Require vasopressors after cardiac surgery as a result of cardiopulmonary bypass-induced hypotension.
  • Who have a specific indication for catecholamine therapy other than shock (i.e. angioedema or intracranial hypertension).
  • If the attending team has agreed to withhold or withdraw life sustaining care.
  • Concurrent enrollment in interventional trials that do not meet guidelines (see ccctg.ca) for co-enrollment (co-enrollment is permissible if there is no potential interaction between the protocols; this will be addressed case by case).
  • Prior randomization in this study.

Key Trial Info

Start Date :

April 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2015

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT01800877

Start Date

April 1 2013

End Date

February 1 2015

Last Update

March 12 2019

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

Mercy Hospital

St Louis, Missouri, United States, 63141

2

University of Alberta Hospital

Edmonton, Alberta, Canada

3

Queens Elizabeth II Hospital

Halifax, Nova Scotia, Canada

4

Kingston General Hospital

Kingston, Ontario, Canada, K7L 2V7